Compare AbCellera Biologics Inc (ABCL) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $8.92 (market cap $2.85B), while Vanguard Dividend Appreciation Index Fund ETF trades at $246.54. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | VIG | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | — |
52-Week High | $9.76 | $245.79 |
52-Week Low | $2.78 | $208.67 |
Enterprise Value | $2.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
VIG trades at $245.23, up 0.35% over 24 hours, with a bullish technical signal driven by moving averages and a dividend of $1.00 scheduled for June 2026. The ETF focuses on dividend growth, holding stocks like Broadcom, which has surged 710% over five years (24/7 Wall Street, 2026-07-22).
The outlook is positive for long-term investors seeking steady income, supported by a 20-year dividend growth streak, but risks include high RSI levels indicating overbought conditions and potential market volatility from AI and interest rate uncertainties (Zacks Investment Research, 2026-07-30).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
